Rapid immune reconstitution of SCID-X1 canines after G-CSF/AMD3100 mobilization and in vivo gene therapy-Reference-Cited by-同舟云学术

Rapid immune reconstitution of SCID-X1 canines after G-CSF/AMD3100 mobilization and in vivo gene therapy

Published:2018-05-02 Issue:9 Volume:2 Page:987-999
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Humbert Olivier¹,Chan Frieda¹,Rajawat Yogendra S.¹,Torgerson Troy R.²³,Burtner Christopher R.¹,Hubbard Nicholas W.²⁴,Humphrys Daniel¹,Norgaard Zachary K.¹,O’Donnell Patricia⁵,Adair Jennifer E.¹⁶,Trobridge Grant D.⁷,Scharenberg Andrew M.²³⁴,Felsburg Peter J.⁵,Rawlings David J.²³⁴,Kiem Hans-Peter¹⁶⁸

Affiliation:

1. Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, WA;

2. Center for Immunity and Immunotherapies, Seattle Children’s Research Institute, Seattle, WA;

3. Department of Pediatrics and

4. Department of Immunology, University of Washington, Seattle, WA;

5. Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA;

6. Department of Medicine, University of Washington School of Medicine, Seattle, WA;

7. Department of Pharmaceutical Sciences, Washington State University, Pullman, WA; and

8. Department of Pathology, University of Washington School of Medicine, Seattle, WA

Abstract

Key PointsIV delivery of FV vector using the phosphoglycerate kinase promoter outperforms EF1α-containing vector in the canine SCID-X1 model. G-CSF/AMD3100 mobilization before in vivo FV vector delivery improves kinetics and clonal diversity of lymphocyte reconstitution.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/2/9/987/880913/advances016451.pdf

Reference61 articles.

1. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency;Buckley;N Engl J Med,1999

2. Transplantation outcomes for severe combined immunodeficiency, 2000-2009;Pai;N Engl J Med,2014

3. A modified γ-retrovirus vector for X-linked severe combined immunodeficiency;Hacein-Bey-Abina;N Engl J Med,2014

4. Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency;De Ravin;Sci Transl Med,2016

5. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor;Noguchi;Science,1993

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prime editing in hematopoietic stem cells—From ex vivo to in vivo CRISPR-based treatment of blood disorders;Frontiers in Genome Editing;2023-03-10

2. Gene therapy for inborn error of immunity – current status and future perspectives;Current Opinion in Allergy & Clinical Immunology;2022-12-06

3. In Vivo Hematopoietic Stem Cell Genome Editing: Perspectives and Limitations;Genes;2022-11-27

4. Gene Therapy for Inborn Errors of Immunity;Hematology/Oncology Clinics of North America;2022-08

5. Immunological barriers to haematopoietic stem cell gene therapy;Nature Reviews Immunology;2022-03-17